| Trial ID: | L0826 |
| Source ID: | NCT03413722
|
| Associated Drug: |
Tacrolimus
|
| Title: |
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Tacrolimus|DRUG: Everolimus
|
| Outcome Measures: |
Primary: Change in cognitive function, Change from Baseline to Week 12 | Secondary: Change in cerebral blood flow, Change from Baseline to Week 12
|
| Sponsor/Collaborators: |
Sponsor: University of Kansas Medical Center | Collaborators: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
30
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2018-02-01
|
| Completion Date: |
2022-10-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-22
|
| Locations: |
University of Kansas Medical Center, Kansas City, Kansas, 66160, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03413722
|
